-+ 0.00%
-+ 0.00%
-+ 0.00%

Anteris secures CMS Medicare reimbursement eligibility for PARADIGM trial under TAVR policy

PUBT·04/28/2026 10:24:07
Listen to the news
Anteris secures CMS Medicare reimbursement eligibility for PARADIGM trial under TAVR policy
  • Anteris Technologies secured U.S. Medicare reimbursement eligibility for its global pivotal PARADIGM Trial under a CMS national coverage policy.
  • Eligible procedures at participating U.S. study sites will be covered under the TAVR National Coverage Determination 20.32.
  • The Coverage with Evidence Development framework is expected to support U.S. site activation for the PARADIGM Trial.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anteris Technologies Global Corp. published the original content used to generate this news brief on April 28, 2026, and is solely responsible for the information contained therein.